

Perspectives on assistive technology for improving gait performance of children with Cerebral Palsy in daily-life: requirements, needs and wishes

Cristina Bayón (✉ c.bayoncalderon@utwente.nl)

University of Twente

Marleen Hoorn

University of Twente

Antonio Barrientos

Centro de Automática y Robótica, Universidad Politécnica de Madrid, Consejo Superior de Investigaciones Científicas

Eduardo Rocon

Centro de Automática y Robótica, Universidad Politécnica de Madrid, Consejo Superior de Investigaciones Científicas

Joyce P. Trost

Gillette Children's Specialty Healthcare

Edwin H.F. Asseldonk

University of Twente

Research Article

Keywords: Ankle-Foot orthosis, Cerebral Palsy, Gait, Daily-life, Assistive technology

Posted Date: February 18th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1358101/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Perspectives on assistive technology for improving gait performance of children with Cerebral Palsy in daily-life: requirements, needs and wishes

Cristina Bayón^{1,2*}, Marleen van Hoorn¹, Antonio Barrientos², Eduardo Rocon², Joyce P. Trost³ and Edwin H.F. van Asseldonk¹

Abstract

Background: Ankle-foot orthoses (AFOs) are extensively used as a primary management method to assist walking and ambulation of children with Cerebral Palsy (CP). However, there are certain barriers that hinder their prescription and as well as their use as a mobility device in all kinds of daily-life activities. This research attempts to further understand the existing limitations of current AFOs to promote a better personalization of new design solutions.

Methods: Stakeholder (professionals in CP and end-users with CP) perspectives on AFO technology were collected by two online surveys. Respondents evaluated the limitations of current assistive solutions and assessment methods, provided their expectations towards a new AFO design, and analyzed importance of different design features and metrics to enrich the gait performance of these patients in daily-life. Quantitative responses were rated and compared with respect to their perceived importance. Qualitative responses were classified into themes by using content analysis.

Results: 130 survey responses from ten countries were analyzed, 94 from professionals and 36 from end-users with CP. The most highly rated design features by both stakeholder groups were the comfort and the ease of putting on and taking off the assistive device. In general, professionals preferred new features to enrich the independence of the patient by improving gait at functional levels. Responses from end-users also considered their social acceptance and participation. Health-care professionals reported a lack of confidence concerning decision-making about AFO prescription. The relation between the type of assistance required to each pathological gait was not straightforward, and they agreed that more information about patients' day-to-day walking performance would be beneficial.

Conclusion: This research emphasizes the importance of developing new approaches to assess and treat CP gait in daily-life situations. The stakeholders' needs and criteria reported here may serve as insights for the design of future assistive devices and for the follow-up care of these patients.

Keywords: Ankle-Foot orthosis; Cerebral Palsy; Gait; Daily-life; Assistive technology

1 Background

2 Physical disabilities derived from neurological or motor
3 disorders are a global societal problem. In young, Cerebral
4 Palsy (CP) is the major cause of physical disability such
5 as gait limitations [1]. CP results from a damage to the
6 child's brain during birth or early childhood, which may
7 lead to permanent neurological impairments related to mo-
8 tor control, strength, muscle dysfunction, balance and/or
9 posture [2]. According to the Cerebral Palsy Alliance Re-
10 search Foundation [3], 18 million people are living with CP
11 worldwide, with an estimated lifetime care cost of around
12 €1 million per individual [4]. This implies a real impact on
13 the individual, and a true financial burden for the families
14 in particular and society in general [5, 6].

15 The improvement of walking ability is considered one
16 of the primary goals to allow for a more active and inde-
17 pendent lifestyle in CP [2, 7]. In conjunction with other
18 medical, surgical, and therapeutic interventions, assistive
19 devices are essential in the management of gait and mobil-
20 ity of these patients [7–9].

21 Due to the role of the ankle joint in gait [7] and the
22 greater muscle dysfunction of distal lower-extremity mus-
23 cles in CP [10, 11], ankle-foot orthoses (AFOs) are the fore-
24 most used type of assistive devices [7–9, 12–15]. Techno-
25 logical advances over the last decades have resulted in the
26 development of AFO designs for CP, which are typically
27 prescribed depending on (1) the pathological gait pattern
28 and (2) the functional capacities (level of the Gross Motor
29 Function Classification System, GMFCS) of the child [8, 9].
30 As such, based on the literature [2, 8, 15–17] it is possible
31 to obtain a general relationship between the level of motor
32 impairments and the most commonly recommended AFO
33 solutions and other management methods (Appendix A).

34 *Correspondence: c.bayoncalderon@utwente.nl

35 ¹Department of Biomechanical Engineering, University of Twente,

36 Enschede, The Netherlands

37 ²Centro de Automática y Robótica, Universidad Politécnica de Madrid,
Consejo Superior de Investigaciones Científicas, Madrid, Spain

38 ³Gillette Children's Specialty Healthcare, Minnesota, United States

39 Full list of author information is available at the end of the article

However, this general relationship is too broad with respect¹
to the *ideal* orthotic management that should be prescribed²
to tailor the specific needs of an individual patient. First,³
current clinical standards for choosing all possible AFO⁴
design features and the impact of these features on patient⁵
outcomes in daily-life are unclear [13, 18–20]. Second, the⁶
assessment of the patient's walking *capacity* in a laboratory⁷
is not always representative of the patient's walking *perfor-*⁸
mance in real life [20, 21]. Additional information about⁹
the patient's community walking activities would be bene-¹⁰
ficial to better understand their gait problems and improve¹¹
the design and prescription of the different AFO solutions.¹²

Another crucial factor is that traditional AFO designs¹⁵
are normally passive and present considerable limitations¹⁶
related with decreasing push-off power, which is associ-¹⁷
ated with an increased walking energy cost and compensa-¹⁸
tions around the hip [12]. In the last years, adjustable dy-¹⁹
namic response AFOs (ADR-AFOs) have been introduced²⁰
to the market giving greater adjustability of the AFO by²¹
the clinician to the specific patient's needs. This type of²²
instrumented orthosis allows variable ankle range of mo-²³
tion (ROM) and selective support for the tibialis anterior²⁴
and gastrocnemius-soleus muscles, storing and releasing²⁵
energy during gait. Thus, they aim to make walking more²⁶
natural and flexible while preventing the increase of pa-²⁷
tient's walking energy cost associated to a limited push-off.²⁸
Although ADR-AFOs introduce promising advances, the²⁹
benefits are still variable depending on the type of patient³⁰
and/or walking scenario [12–14, 22, 23]. One of their bigger³¹
limitations is the difficulty of choosing the correct spring³²
module (desired stiffness) for each patient [12]. Also, simi-³³
lar to traditional designs, ADR-AFOs present limited mod-³⁴
ularity (i.e. impossibility to 'grow up' with the child) [24].³⁵
This, together with their poor adaptability to challenging³⁶
mobility tasks and ground variations encountered during³⁷
daily-life [7, 25], make them (still) ineffective solutions to³⁸
be employed in all varieties of everyday activities [12, 23].³⁹

¹ An emerging trend to address the shortcomings of pervi-
²ous AFO designs is the design of untethered robot-assisted
³AFOs [26, 27]. The possibilities of control and actuation of
⁴these solutions allow a wide range of adaptability to both
⁵the patient and the environment. However drawbacks as
⁶daily-life devices include weight, bulkiness, comfortability,
⁷battery duration and operability [26, 27].

⁸ The purpose of this study is to improve understanding
⁹of the requirements to assist gait in CP, aiming to enrich
¹⁰potential dynamic design solutions for better walking per-
¹¹formance in daily-life activities. When aiming to improve
¹²physical functions in CP, it is recommended [28] to first set
¹³the user-chosen goals as well as to focus on practice within
¹⁴a real-life context. According to these recommendations,
¹⁵here we assess and compare perspectives of stakeholders
¹⁶(professionals in CP and end-users with CP) on assistive
¹⁷technology for improving gait performance, with respect to
¹⁸perceived importance of design features, expectations to-
¹⁹wards a new design and potential changes in current de-
²⁰vices. This allows us to answer two main research ques-
²¹tions: (1) *Which improvements to current/conventional as-*
²²*istive technology are needed to facilitate and enrich gait*
²³*performance in daily-life activities?*; and (2) *How can real-*
²⁴*world gait measures inform clinical decision-making when*
²⁵*assessing patients' progression and prescribing new assis-*
²⁶*tive devices?*

²⁷

²⁸Methods

²⁹Study design

³⁰Two online surveys (formulated in English) were developed
³¹following the flow-chart of Figure 1, and used to collect
³²the answers from two stakeholder groups: (1) professionals
³³in CP (G_P), with a special focus on the health-care sector
³⁴(i.e. physiotherapists, rehabilitation physicians, surgeons,
³⁵orthotists), but also including others, such as non-clinical
³⁶researchers or equipment vendors; and (2) end-users with
³⁷CP (G_U). The research ethics board of the University of
³⁸Twente approved the English versions of the surveys (refer-
³⁹ence number 2021.91). Subsequently, they were also trans-

lated into Spanish and Dutch by native speakers (CB, MvH¹
 and EHFvA), who discussed the content and intent of the²
 questions to facilitate the accurate translations.³


The final versions can be found in the Additional Files 1⁴
 and 2. All collected responses were anonymous. The pro-⁵
 tocols for data protection of the affiliations involved were⁶
 applied.⁷

⁸

⁹Survey for G_P : professionals in CP

The final version of the survey for group G_P consisted of 57¹⁰
 questions classified within six clusters (see Additional File¹¹
 1): (1) *Demographics*; (2) *Gait management and AFO pre-*¹²
scription, composed by questions that were only answered¹³
 by those professionals working in the health-care sector;¹⁴
 (3) *Importance of design features*, with questions related¹⁵
 to usability and aesthetic considerations, functional consid-¹⁶
 erations, and practical considerations. Within this cluster,¹⁷
 health-care professionals were asked two extra questions¹⁸
 related to which kind of assistance (i.e. support push-off,¹⁹
 inhibit foot-slap and prevent drop-foot) would they apply to²⁰
 the different types of pathological gait in CP and to the five²¹
 levels of the GMFCS; (4) *Relevant in-home metrics*, which²²
 included questions referred to general, temporal, spatial²³
 and ground clearance parameters; (5) *Gait in daily-living*,²⁴
 with an open-ended (OE) question “Which daily-life ac-²⁵
 tivities would benefit from improved gait performance in²⁶
 children with CP?”; and (6) *Limitations of current devices*,²⁷
 including two OE questions “What changes to the current²⁸
 exoskeletons are needed to improve walking in daily-life²⁹
 situations?” and “What changes to the current AFOs are³⁰
 needed to improve walking in daily-life situations?”.³¹

Closed-ended (CE) questions primarily used a multiple-³²
 choice response format (*Demographics*), or a 5-point Lik-³³
 ert scale, with Likert scales ranging from 1–strongly dis-³⁴
 agree to 5–strongly agree (*Gait management and AFO pre-*³⁵
scription), or 1–very unimportant to 5–very important (*Im-*³⁶
portance of design features and *Relevant in-home metrics*).³⁷
 In the latter case, after respondents selected the importance³⁸
 for each of the different factors, they were asked about their³⁹



top-3 most important factors to differentiate in case they ranked all of them as ‘important’ or ‘very important’.

Survey for G_U : end-users with CP

The final version of the survey for group G_U was composed of a total of 41 questions (Additional File 2), which were classified in five clusters: (1) *Demographics*; (2) *Importance of design features*, similarly to what was presented for G_P ; (3) *Expectations to a new design*, whose questions were based and adapted from the Unified Theory of Acceptance and Use of Technology questionnaire (UTAUT)[29]. These were referred to effort expectancy (EE, degree of ease associated with the use of the new system), perfor-

mance expectancy (PE, degree to which the patient believes that using the new system will help them to attain gains in walking performance), social influence (SI, degree to which the patient’s behaviour is influenced by the way in which they believe others will view them as a result of using the new technology), and facilitating conditions (FC, degree to which the patient believes that daily-life infrastructures facilitate the use of the system); (4) *Gait in daily-living*; and (5) *Limitations of current devices*, both clusters (4) and (5) included OE questions similar to those presented for G_P .

¹ For G_U , we used a multiple-choice response format for
² the *Demographics*, and 5–point Likert scales, with 1–very
³ unimportant to 5–very important for *Importance of design*
⁴ *features*, and with 1–strongly disagree to 5–strongly agree
⁵ for *Expectations towards a new device*. Like G_P , respon-
⁶ dents were asked about their top-3 most important factors
⁷ in the cluster *Importance of design features* to differentiate
⁸ in case they rated all of them as ‘important’ or ‘very im-
⁹ portant’. In the surveys for G_U , several questions were also
¹⁰ accompanied by pictures to enhance the reader’s compre-
¹¹ hension.

¹³ Participants

¹⁴ Participants were recruited using snowball sampling. Data
¹⁵ were collected between July and October, 2021.

¹⁷ The study information for G_P , including the survey link,
¹⁸ was primarily sent by email to eligible contacts within
¹⁹ our international network. This comprised several hospi-
²⁰ tals and rehabilitation centers in Spain, The Netherlands
²¹ and The United States, companies in The Netherlands and
²² Germany, and other researchers affiliated with institutions
²³ in Spain, The Netherlands, The United States, Switzerland
²⁴ and Colombia. The invitations included a request to for-
²⁵ ward the link to other eligible professionals to maximize
²⁶ its distribution.

²⁷ The target population to complete the survey of G_U were
²⁸ primarily patients with CP. In cases where patients were un-
²⁹ able to answer the survey (e.g. too young to understand the
³⁰ questions, severe cognitive impairment), parents or legal
³¹ caregivers gave their responses instead. The main strategy
³² to approach end-users to complete the survey was through
³³ the previously contacted hospitals and rehabilitation cen-
³⁴ ters.

³⁵ Besides the distribution by email, we also advertised both
³⁶ surveys by flyers in hospital waiting rooms and on social
³⁷ media (i.e. Twitter).

³⁸ Additionally, the authors CB and MvH had informal con-
³⁹ versations with several professionals in the field and end-

users, which allowed a richness to the answers of the pre-¹
 vious surveys.²

Data analysis

Responses to both surveys were exported into an Excel⁵
 file for data cleaning and analysis. Spanish and Dutch re-⁶
 sponses were translated into English by two bilingual re-⁷
 searchers (CB and MvH).⁸

Closed-ended responses

Descriptive statistics and graphic representations were used¹⁰
 to summarize and compare CE responses. For the clus-¹¹
 ter *Importance of design features*, the Mann-Whitney U¹²
 test with $\alpha = 0.05$ was performed in Matlab 2018b (Math-¹³
 works, Natick, MA, USA) to determine significant differ-¹⁴
 ences between both stakeholder groups.¹⁵

Open-ended responses

Responses to the OE questions were analyzed using con-¹⁸
 tent analysis [29]. Irrelevant answers (e.g. “I don’t know”)¹⁹
 were removed prior to starting the analysis. Data were im-²⁰
 ported into ATLAS.ti 9 (ATLAS.ti GmbH, Berlin, Ger-²¹
 many), and responses were reread multiple times to identify²²
 the key thoughts, impressions and concepts. Inductive cod-²³
 ing was used to sub-categorize the responses, and the re-²⁴
 sultant subcategories were grouped into emergent broader²⁵
 themes through discussion (CB and MvH). Frequencies of²⁶
 themes and subcategories were assessed. Responses could²⁷
 be coded with more than one theme.²⁸

Results

Participants

A total of 94 professionals and 36 end-users responded to³²
 the surveys. Demographic information about the respon-³³
 dents is described in Tables 1 and 2 for G_P and G_U respec-³⁴
 tively.³⁵

Gait management and AFO prescription

Health-care professionals (83 out of 94 respondents) were³⁷
 asked to agree or disagree (1–strongly disagree to 5–³⁸
 strongly agree) with four statements about current gait³⁹

Table 1 Demographics of G_P stakeholder.

Professionals in CP (n_{G_P} = 94)	Frequency	Percent
Sex		
Male	35	37.2%
Female	59	62.8%
Age		
18–24	0	0%
25–34	22	23.4%
35–44	37	39.4%
45–54	22	23.4%
55–64	9	9.6%
65 or above	4	4.3%
Country		
Spain	45	47.9%
The Netherlands	31	33.0%
USA	9	9.6%
Belgium	2	2.1%
Colombia	1	1.1%
Ecuador	1	1.1%
Mexico	1	1.1%
Switzerland	1	1.1%
Prefer not to answer	3	3.2%
Profession		
Physiotherapist	50	53.2%
Rehabilitation physician	17	18.1%
Researcher	13	13.8%
Surgeon	3	3.2%
Equipment vendor	3	3.2%
Orthotist	2	2.1%
Other*	6	6.4%
Time working in the field		
less than 1 year	0	0%
1–4 years	8	8.5%
5–10 years	21	22.3%
11+ years	65	69.1%
Experience with AFOs for CP		
Yes	78	83.0%
No	16	17.0%
Experience with exo or ADR-AFO		
Yes	27	28.7%
No	67	71.3%

Table 2 Demographics of G_U stakeholder.

End-Users with CP (n_{G_U} = 36)	Frequency	Percent
Sex		
Male	19	52.8%
Female	16	44.4%
Prefer not to disclose	1	2.8%
Age		
Under 3	3	8.3%
3–7	13	36.1%
8–12	11	30.6%
13–17	5	13.9%
18 or above	3	8.3%
Prefer not to answer	1	2.8%
Country		
Spain	20	55.6%
The Netherlands	5	13.9%
USA	3	8.3%
Belgium	3	8.3%
Peru	2	5.6%
Chile	1	2.8%
Prefer not to answer	2	5.6%
Level of GMFCS		
GMFCS I	7	19.4%
GMFCS II	13	36.1%
GMFCS III	3	8.3%
GMFCS IV	9	25.0%
GMFCS V	4	11.1%
Experience with exo or ADR-AFO		
Yes	11	30.6%
No	25	69.4%
Type of AFO currently using*		
GRAFO	1	2.8%
SAFO	15	41.7%
HAFO	12	33.3%
PLS-AFO	4	11.1%
ADR-AFO	2	5.6%
SPM	2	5.6%

*See Appendix A for the description of AFO types

*Other professions as occupational therapist, podologist...

management in CP and the challenges to assess specific user's needs for their daily-life activities.

Only 44.6% of the health-care professionals agreed (or strongly agreed) with the statement “There is enough information to feel confident when prescribing the correct AFO type (solid, hinged, ADR...) for a specific patient”, which indicates that more than 50% of the respondents think that more information is required.

As many as 79.3% of the respondents believed (i.e. agreed or strongly agreed) that “patients' performance in the clinic is different than in real-life settings”. This might be related to the fact that almost all the health-care professionals (98.8%) considered that “it would be important to get information about patients' walking on daily-life activities”, and that the 95.2% of them agreed with the statement “A report on the use of AFOs on daily-life could provide useful information to improve the patient's assessment in clinic”.

Importance of design features

Both stakeholder groups (G_P and G_U) rated 18 design features on a Likert scale from 1—very unimportant to 5—very important. All features were rated to be important for the majority of all respondents (i.e. $\geq 60\%$ of respondents from both groups, Figure 2). “Ease of putting-on/taking-off” and “comfort while wearing” were rated as ‘important’ or ‘very important’ by more than 90% of respondents from both stakeholder groups.

G_P and G_U agreed on their top priority for usability and aesthetic considerations and for practical considerations (Figure 2). However, there was no consensus for functional considerations: professionals selected “adaptability to walking terrain” as their top priority, while end-users preferred “replicability of normal walking patterns”.

The Mann-Whitney U tests reported significant differences between the perceived importance for each stakeholder group for three features: end-users' perceived importance was significantly larger than professionals' for “replicability of normal walking patterns” ($U = 5.52e03$,

$p = 0.001$, $\text{Median}_{G_P} = 4$, $\text{Median}_{G_U} = 5$) and “adaptability to walking speed” ($U = 5676$, $p = 0.006$, $\text{Median}_{G_P} = 4$, $\text{Median}_{G_U} = 5$). Contrarily, end-users perceived the feature “low amount of learning/mental effort required to use the device” less important than professionals ($U = 6619$, $p < 0.01$, $\text{Median}_{G_P} = 5$, $\text{Median}_{G_U} = 4$). For the rest of the features we did not find significant differences, but overall (15 out of 18 features), professionals rated the features as more important than end-users did.

Type of walking assistance

Health-care professionals answered two additional questions to identify the type of ankle assistance that should be applied depending on the pathological gait and level of GMFCS (Figure 3). In their responses they considered that the assistance to prevent drop-foot has a greater benefit for cases of CP that are less severe, while the assistance in push-off becomes more important with more severe gait patterns as apparent equinus or crouch gait (Figure 3-(a)). Besides, the patients that would benefit the most from the three types of support evaluated are those classified within levels I+ and III- of the GMFCS (Figure 3-(b)).

End-users' expectancy towards a new device

The overall perception and expectancy of G_U towards a new device is presented in Figure 4 for the four constructs of the (adapted) UTAUT [30]. The end-users' acceptance to adopt and use a new system is mostly positive. Although it is expected that some effort will be required to operate the system, the effort is worth perceived as the users expect that the device will improve their gait performance and social influence: averaged percentages of acceptance (i.e. ‘agree’ or ‘strongly agree’) for each construct are 46.53% — EE, 73.15% — PE, 70.27% — SI and 67.35% — FC. Note that for the quantification of averaged percentages of acceptance, negative statements like “it will take too long to learn how to use the system” were reversely counted.




Figure 2 Percentage of respondents who ranked the design features as 4–important or 5–very important. Significant differences between G_P and G_U reported by the Mann-Whitney U tests are marked with (*). The darker bars represent those features that were selected as the top priority by the respondents within each category (a), (b) and (c).

Relevant in-home metrics

Descriptive statistics were used to represent the rated importance for each potential metric to assess patient’s performance in daily-life (Table 3). The most important selected features (top-1) of each category were the gait asymmetry, the stance duration, the angle between foot and shank at heel strike, and the minimum toe clearance at mid-swing. Besides the top selected features, more than 70% of respondents also considered ‘important’ or ‘very important’ the factors of cadence, stride length, gait speed, and the foot-shank angle at both toe-off and mid-stance (Table 3).

Qualitative analysis of open-ended questions

Considering relevant answers, the participation of G_P and G_U was respectively 87.2% and 80.6% for OE1, 63.8% and 47.2% for OE2, and 74.5% and 61.1% for OE3 (complete overview in Appendix B).


OE1: Daily-life activities that would benefit from an improved gait performance

The theme *General mobility* was the foremost mentioned (68.5% of respondents, 70.7% G_P and 62.1% G_U), encompassing subcategories such as Walking (48.6%), Stairs (12.6%) and Running (9.9%).

The second most frequent theme was *Leisure*, with a response rate of 39.6% (45.1% G_P , 24.1% G_U). It encompassed Play (25.2%), Sports (16.2%), and all other activities associated with free time that require full body motor function.

Other identified themes indicated the importance of having a functional gait pattern in specific locations such as *School* (31.5%), *Non-standardized Terrains* (18.9%) and *Home* (16.2%).

Finally, the theme *Equal social interaction* (20.7%) was identified related to the ability to keep up with able bodied peers and family members.



OE2: Limitations of powered exoskeletons for daily-life use

The first theme and main identified problem of powered exoskeletons is their *Bulkiness* (45.5% respondents, 45% G_P , 47.1% G_U), including subcategories as *Weight* (31.2%) and *Volume* (27.3%). The second most frequent theme was *User friendliness* (39.0%), followed by *Cost* (29.9%), *Control* (28.6%), and *Adaptability* (20.8%) of the device.


Themes with lower frequencies were *Availability* (11.7%), understood as the possibility of getting access to an exoskeleton, *Flexibility & ROM* (7.8%), *Acceptance* (6.5%)

and *Durability* (5.2%), the last two only mentioned by the group of professionals (Appendix B).

OE3: Limitations of passive AFOs for daily-life use

The most important problem of current AFOs and principal theme based on G_U is the lack of *Comfort* (21.4% G_P , 50% G_U). In the case of G_P , the predominant limitation of current AFOs is the *Adaptability* of these devices (55.7% G_P , 36.4% G_U) to both patient's needs (i.e. type and level of assistance) and environment (i.e. type of walking surface).

Other identified themes were *Flexibility & ROM* (22.7%), *Bulkiness* (17.4%), *Wearability* (9.8%), specifically referring to the difficulties to combine AFOs with clothing



and shoes, *Metrics* (9.8%), with answers like “Possibility to test different AFO models with quantitative metrics to evaluate which solution is the best for a specific patient”, *User friendliness* (9.8%), *Cost* (8.7%), *Durability* (6.5%) and the improvement of general *Walking* (5.4%). In the latter, professionals highlighted the necessity to improve ‘Functional’ Walking, while end-users stressed the desire of generating ‘Normal’ Walking patterns with AFOs (Appendix B).

The necessity of new AFOs that reduce *Energy cost* was a theme mentioned by 20% of professionals, but not by the end-users group.

Discussion

Summary of the results

The present study was designed to collect the requirements, needs and wishes on the AFO technology to improve gait performance of individuals with CP in daily-life situations. The results derived from the surveys provide insights on the stakeholders’ needs and criteria to assist pathological gait in CP, highlighting important required features that might be useful for both (1) the assessment and prescription of current AFOs, and (2) the development of future novel devices.

In total, 94 professionals in CP (83 of them working within the health-care sector) and 36 end-users with CP (patients or families) responded to the surveys. We acknowledge that some individuals with CP who answered

the questionnaire and who are affected by severe motor impairments (i.e. GMFCS V) are maybe unlikely to benefit from assistive AFOs to promote their walking capabilities in daily-life. However, the survey participation was not restricted in that regard because we think it is important to also recognize the wishes of these users, as they can contribute with small actions to everyday tasks.

The most valuable feature identified by both stakeholder groups in the CE questions was the “comfort while wearing” the assistive device, i.e. avoiding skin pressure, friction or abrasions. This has also been a primary concern of previous studies about the efficacy of AFOs for CP [13], and other studies focused on assistive technology for patients with spinal cord injury or stroke [31]. Both stakeholder groups also highlighted the “ease of putting-on and taking-off” the device. Even considering that “costs for replacement or maintenance” can be substantial during childhood and adolescent growth, the rated importance for these cost features did not stand out compared to the comfortability and usability of the device. This was also reflected in the OE questions, where stakeholders proposed a change to have a more breathable and softer AFO material and a better fit to the child’s foot.

All design features of the survey were considered to be important, but generally professionals rated them higher than end-users did (Figure 2). A clear deviation of this pattern was observed for the “replicability of normal walking patterns”: 62.8% G_P vs 88.6% G_U considered this feature to be ‘important’ or ‘very important’. In this regard, it is worth noting that both stakeholder groups differed when selecting their top functional design feature. While professionals preferred to provide the child with higher autonomy by making the AFO “adaptable to different walking terrains”, end-users with made their preference for having a “more normal walking pattern”. The reason behind this might be that professionals are considering the improvements on functional gait levels, but end-users are thinking

more about social acceptance and participation at task levels.

Under functional considerations (Figure 2-(b)), the feature with the highest percentage of importance rating was not selected as the top-1 priority by any stakeholder group (although it was in their top-2 or top-3). The same occurs when selecting the top-1 general parameter under *Relevant in-home metrics* (Table 3). This could be seen as an apparent inconsistency, but the explanation for this might be that respondents sometimes scored features with 4–important or 5–very important indistinctly, and they only selected their real first preference when being asked for their top priorities among the scored ones. That confirms the importance of including in the surveys a question for prioritizing the rated features.

Evaluating the classification of the type of walking assistance that professionals working in the health-care sector made (Figure 3), it is possible to observe some clear trends when these assistance types are evaluated with respect to the level of the GMFCS: (1) patients classified within level GMFCS I normally have the ability to walk, so not that much extra assistance of any type is needed in those cases; (2) patients classified within levels GMFCS IV and V can barely walk, so they do not benefit that much from the assistances conceived here; and (3) patients classified within GMFCS I+ and III are the ones that can benefit the most from the extra support provided by dynamic AFOs. In these cases, the prevention of drop-foot is more important for less severe gait patterns (GMFCS I+ and II), while the push-off support becomes more important as the severity of the gait pattern increases (GMFCS II+ and III). However, each level of GMFCS involves heterogeneous patient’s behaviours [21], and as such, the relationship between Figure 3-(a) and Figure 3-(b) is not direct nor trivial. Although there is an overlap (i.e. drop-foot gait is mostly seen in GMFCS I and crouch gait in GMFCS III), children classified between levels I+ and III can exhibit any type of the pathological gait patterns presented.

¹ The not trivial connection between the level of the GM-
²FCS, the patient's pathological gait and the type of as-
³sistance needed makes it hard to prescribe the most suit-
⁴able AFO for a specific patient [13, 18]. This fact was also
⁵expressed in the cluster *Gait management and AFO pre-*
⁶*scription* of the survey, where health-care professionals re-
⁷ported a lack of confidence concerning decision-making
⁸about AFO prescription. This might (also) be related to
⁹the fact that more than 79% of health-care professionals
¹⁰thought that the performance of patients in the laboratory
¹¹(e.g. gait analysis) is different than in real-life settings. This
¹²behaviour has been a long investigation of psychologists
¹³and it is known as the 'Hawthorne effect' [32], which states
¹⁴that humans act differently if they think they are being ob-
¹⁵served. The Hawthorne effect has previously been verified
¹⁶in children with CP [20, 21], suggesting that their walking
¹⁷capacity demonstrated in a standardized environment (lab-
¹⁸oratory) is usually overestimated and exceeds their walking
¹⁹performance in real-life settings. That is likely the reason
²⁰why around 98% of the health-care professionals empha-
²¹sized the importance of gathering information regarding the
²²use of assistive technology at home, as this may enrich the
²³assessments and evaluations at the clinic. Table 3 gave an
²⁴overview in this regard, about the rating importance given
²⁵by the professionals in CP for the principal in-home metrics
²⁶to be collected. These in-home metrics would be useful not
²⁷only to assess the patient's performance, but also to evalu-
²⁸ate different AFO models using quantitative parameters, as
²⁹it was stated by the respondents in the OE questions.

30

31

32 Implications for future devices

33 New and effective approaches are needed to assess and
34 treat CP pathological gait in non-standardized settings. Ex-
35 isting traditional solutions present an inherent function as
36 mobility devices not adaptable to specific patient's needs.
37 Although there have been promising advances (especially
38 with the dynamic ADR-AFOs), they still lack the neces-
39 sary evidence to demonstrate the adaptability to different

scenarios and the achievement of lasting improvements and¹
long-term effects in general gait quality [12–14, 22, 23].²

For new AFO designs, the benefits of powered robotic³
technology should be considered. User's expectations to⁴
adopt a new solution are positive. However, it is key to put⁵
effort in addressing the current problems identified by the⁶
respondents of this survey, including the comfort, weight,⁷
bulkiness, safety, operability and user-friendliness of the⁸
powered devices. These are crucial factors for the imple-⁹
mentation of assistive devices in daily-life, and are also re-¹⁰
lated to the features referred in a recent article [33] for the¹¹
adoption of robotic technology for pediatric rehabilitation.¹²
Moreover, to satisfy the requirements of both health-care¹³
professionals and end-users, there should be a trade-off be-¹⁴
tween the improvement of functional levels, the provision¹⁵
of higher autonomy, and the social acceptance while using¹⁶
the device.¹⁷

Finally, the implication of sensors within the design of¹⁸
new AFOs might be an option to provide metrics and as-¹⁹
sess the user's gait in daily-life to inform clinical decision-²⁰
making.²¹

22

23 Study limitations

We got respondents from ten different countries in total,²⁴
however, Spain and The Netherlands were the ones com-²⁵
prising the majority of the answers. This might provoke²⁶
some bias with the representation of the broader world pop-²⁷
ulation. A second bias might come from the voluntary na-²⁸
ture of participation in the online surveys, which might²⁹
cause that some questions are responded positively towards³⁰
the necessity of new changes in current gait assistive tech-³¹
nology for CP [34].³²

In the surveys, we tried to enhance the reader compre-³³
hension both with the way of formulating the questions³⁴
and the accompaniment of illustrations. Overall, we found³⁵
a general consensus in the answers, which might indicate³⁶
that the questions were properly understood. However, we³⁷
cannot entirely guarantee or demonstrate that all partici-³⁸
pants answered the online surveys properly, as our method-³⁹

ology does not afford examination of respondents' knowledge levels.

3

4 **Conclusion**

5 This study provides insights into the weighted desires of
6 children with CP, families and professionals in the field, to-
7 wards the use and design of (AFO) assistive devices. The
8 study is not meant to be a resolute guide, nor does it attempt
9 to rationale for the biomechanical basis to influence in gait
10 performance, but it should be considered as important in-
11 formation to determine the new future designs of these as-
12 sistive devices.

13 With this research we tried to give clarity on (1) what
14 needs to be improved in current assistive technology to en-
15 rich gait in daily-life activities, and (2) what type of day-to-
16 day performance measurements may allow better person-
17 alization of gait management and AFO prescription. The
18 outcomes of our investigation bring different and comple-
19 mentary information, which is valuable for both designers
20 of assistive devices for CP and clinicians involved in treat-
21 ment and follow-up care of these patients.

22

23 **Appendix A**

24 In the following table we report a relationship between the
25 most predominant pathological gaits in CP and the pri-
26 mary management methods currently applied. The tradi-
27 tional AFOs considered for orthotic management are:

- 28 • Ground reaction AFO (GRAFO): rigid orthosis with a
29 ventral shell that blocks any movement of the anatom-
30 ical ankle joint in the interest of enabling knee exten-
31 sion in terminal stance
- 32 • Solid AFO (SAFO): rigid orthosis covering the foot
33 and the shank with a dorsal shell that blocks any
34 movement of the anatomical ankle joint
- 35 • Hinged AFO (HAFO): orthosis with a dorsal shell
36 that blocks any plantarflexion but enables dorsiflex-
37 ion with a defined pivot point in the anatomical ankle
38 joint. It does not have a spring effect nor a dorsiflexion
39 stop

- Posterior leaf-spring AFO (PLS-AFO): orthosis with
a leaf spring behind the Achilles tendon. It provides
flexibility at the ankle joint and allows passive ankle
plantar- dorsiflexion during the stance phase. It also
corrects excessive platarflexion during swing
- Supramalleolar AFO (SPM-AFO): used to increase
ankle medio-lateral stability and foot alignment while
allowing full ankle plantar- dorsiflexion

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

1
2
3

4 **Table 3** Descriptive statistics to illustrate the rating importance of
 5 relevant in-home metrics given by Professionals in CP. Bold
 6 features represent the ones selected as the top priority by the
 7 respondents for each category. The percent of importance
 8 includes 4–important + 5–very important.






7	Metrics	Mean	SD	Percent import.	7
8	<i>General parameters</i>				8
9	Cycle duration	3.8	1.0	63.4%	9
10	Cadence	4.0	0.8	76.1%	10
11	Stride length	4.1	0.7	79.4%	11
12	Stride velocity	3.9	0.8	65.6%	12
13	Asymmetry	4.0	0.9	72.3%	13
14	Gait speed	4.1	0.8	81.7%	14
15	<i>Temporal parameters</i>				15
16	Stance duration	4.1	0.9	77.4%	16
17	Swing duration	3.9	0.9	68.5%	17
18	Double support	3.9	0.9	67.7%	18
19	Loading dur.	3.8	1.0	63.4%	19
20	Foot flat dur.	3.8	1.0	62.4%	20
21	Push-off dur.	3.9	1.0	69.2%	21
22	<i>Spatial parameters</i>				22
23	Peak angular vel.	3.7	0.9	64.0%	23
24	Swing speed	3.7	0.9	60.7%	24
25	Strike angle (fs)	4.3	0.9	83.3%	25
26	Toe-off angle (fs)	4.1	1.0	73.3%	26
27	Mid stance angle (fs)	4.0	0.9	77.8%	27
28	Strike angle (fg)	3.9	1.0	67.0%	28
29	Toe-off angle (fg)	3.8	1.0	61.4%	29
30	Mid stance angle (fg)	3.8	1.0	68.5%	30
31	Peak circumduction	3.9	0.9	68.1%	31
32	<i>Ground clearance</i>				32
33	Max. heel clear.	3.3	1.1	46.2%	33
34	Max. toe clear. (ms)	3.6	1.1	55.0%	34
35	Min. toe clear. (ms)	4.1	0.9	74.7%	35
36	Toe clear. (hs)	3.7	1.1	58.9%	36

37 **n_{GP} = 94**

38 fs: foot-shank; fg: foot-ground;
 39 ms: mid-swing; hs: heel strike

37
38
39

Table 4: Relationship between pathological gait types and primary management methods applied.

Pathological gait	Representation and muscles	Characteristics	Prevalence	Orthotic management*	AFO representation	Other management
Drop foot		Drop foot during swing due to inability to control ankle dorsiflexors. No calf contracture, so during stance, dorsiflexion is normal. Lack of first rocker	Rare. Normally it progresses to others more severe	HAFO or PLS-AFO		Not applicable
True equinus (w/o knee recurvatum)		True equinus during stance due to spasticity or contracture of the gastroc-soleus muscles. Drop foot in swing for impaired function in ankle dorsiflexors	Very common	HAFO or PLS-AFO		BTX-A to calf, Tendo Achilles and/or calf lengthening
Jump gait (w/o stiff knee)		Spasticity on hamstrings and hip flexors in addition to calf spasticity/contracture. The ankle is in equinus, with knee and hip in flexion and anterior pelvis tilt	Very common	HAFO, PLS-AFO or SAFO		BTX-A to calf and hamstrings. SEMLS for addressing lever arm dysfunction

39

38

37

36

35

34

33

32

31

30

29

28

27

26

25

24

23

22

21

20

19

18

17

16

15

14

13

12

11

10

9

8

7

6

5

4

3

2

1

39

38

37

36

35

34

33

32

31

30

29

28

27

26

25

24

23

22

21

20

19

18

17

16

15

14

13

12

11

10

9

8

7

6

5

4


3

2

1

1
2
3
4
5
6
7


No BTX-A to the calf, as it would cause crouch gait. SEMLS for addressing lever arm dysfunction



PLS-AFO, SAFO or GRAFO

Common

Progression of pathological gait with child's growth. Ankle has an apparent normal dorsiflexion during stance, but knee and hip are in excessive flexion.



Apparent equinus (w/o stiff knee)


The pathology is normally too advanced to use BTX-A, although if the child is young, BTX-A can be used on HAMS and hip flexors. SEMLS for addressing lever arm dysfunction



GRAFO

Only severe cases

Excessive ankle dorsiflexion during stance in combination with excessive knee and hip flexion.



Crouch gait

*Choice according to the PF-KE couple [35] and other parameters [14]. BTX-A: Botulinum toxin type A; SEMLS: single-event multilevel surgery; TA: tibialis anterior, SOL: soleus, GAS: gastrocnemius, HAMS: hamstrings, RF: rectus femoris

39
38
37
36
35
34
33
32
31
30
29
28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11
10
9
8

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

1 Appendix B

2 Themes overview derived from responses to the OE ques-
3 tions is presented here.

5 Abbreviations

6 CP: Cerebral Palsy; AFO: ankle-foot orthosis; GMFCS: gross motor function
7 classification system; GRAFO: ground reaction AFO; SAFO: solid AFO;
8 HAFO: hinged AFO; PLS-AFO: posterior leaf-spring AFO; SMP-AFO:
9 supramalleolar AFO; ADP-AFO: adjustable dynamic response AFO; ROM:
10 range of motion; G_p: group of professionals in CP responding the survey;
11 G_U: group of end-users (children with CP and families) responding the
12 survey; OE: open-ended; CE: closed-ended; UTAUT: Unified Theory of
13 Acceptance and Use of Technology questionnaire; EE: effort expectancy;
14 PE: performance expectancy; SI: social influence; FC: facilitating conditions;
15 BTX-A: botulinum toxin type A; SEMLS: single-event multilevel surgery; TA:
16 tibialis anterior; SOL: soleus; GAS: gastrocnemius; HAMS: hamstrings; RF:
17 rectus femoris; PF-KE: plantarflexion - knee extension couple.

16 Declarations

17 Ethics approval and consent to participate

18 The local ethical committee at University of Twente gave approval to the
19 study. The study was carried out under reference number 2021.91.
20 Participants gave consent for voluntary participation on filling in the
21 questionnaires.

21 Consent for publication

22 Consent for publication has been given by the participants.

23 Availability of data and materials

24 The anonymized datasets generated and/or analyzed during the current
25 study are available from the corresponding author on reasonable request.

26 Competing interests

27 The authors declare that they have no competing interests.

28 Funding

29 This work has been carried out partly with the financial support from the
30 Ministerio de Ciencia e Innovación and the Agencia Estatal de Investigación
31 of Spain (MCIN/AEI/10.13039/501100011033) under grant
32 FJC2019-039551-I, European Union NextGenerationEU/PRTR; and partly
33 with the financial support from the Dutch Research Council NWO, under the
34 grant Veni-TTW-2020 with reference number 18079.

34 Authors' contributions

35 CB made the conceptualization of the study, performed the data curation
36 and analysis, acquired the funding and wrote the manuscript; MvH helped
37 with conceptualizing the study, analysed the OE questions of the surveys
38 and reviewed the manuscript; AB: contributed with the funding acquisition;
39 ER: contributed with the funding acquisition and reviewed the manuscript;
JPT was part of the technical panel and reviewed the manuscript; EHFvA
contributed in all the facets of the manuscript and funding acquisition.

Acknowledgement

1 Authors would like to acknowledge to all respondents their participation on
2 the surveys, and to the Gillette Children's Specialty Healthcare hospital for
3 reviewing the English versions of the surveys.

Author details

1 Department of Biomechanical Engineering, University of Twente,
2 Enschede, The Netherlands. 2 Centro de Automática y Robótica,
3 Universidad Politécnica de Madrid, Consejo Superior de Investigaciones
4 Científicas, Madrid, Spain. 3 Gillette Children's Specialty Healthcare,
5 Minnesota, United States.

References

1. Novak, I., Morgan, C., Adde, L., Blackman, J., Boyd, R.N.,
Brunstrom-Hernandez, J., Cioni, G., Damiano, D., Darrah, J., Eliasson,
A.-C., de Vries, L.S., Einspieler, C., Fahey, M., Fehlings, D., Ferriero,
D.M., Fethers, L., Fiori, S., Forssberg, H., Gordon, A.M., Greaves, S.,
Guzzetta, A., Hadders-Algra, M., Harbourne, R., Kakooza-Mwesige, A.,
Karlsso, P., Krumlinde-Sundholm, L., Latal, B., Loughran-Fowlds, A.,
Maitre, N., McIntyre, S., Noritz, G., Pennington, L., Romeo, D.M.,
Shepherd, R., Spittle, A.J., Thornton, M., Valentine, J., Walker, K.,
White, R., Badawi, N.: Early, Accurate Diagnosis and Early Intervention
in Cerebral Palsy: Advances in Diagnosis and Treatment. *JAMA*
pediatrics **171**(9), 897–907 (2017).
doi:10.1001/jamapediatrics.2017.1689
2. Armand, S., Decoulon, G., Bonnefoy-Mazure, A.: Gait analysis in
children with cerebral palsy. *EFORT Open Reviews* **1**(12), 448–460
(2016). doi:10.1302/2058-5241.1.000052
3. Cerebral Palsy Alliance Research Foundation: Cerebral Palsy Alliance
Research Foundation - USA (2018).
<https://cparf.org/sstposts/StoryId1607630631242> Accessed
2021-07-28
4. Centers for Disease Control and Prevention: Economic costs
associated with mental retardation, cerebral palsy, hearing loss, and
vision impairment—United States, 2003. *MMWR Morbidity and mortality*
weekly report **53**(3), 57–9 (2004)
5. Tonmukayakul, U., Shih, S.T.F., Bourke-Taylor, H., Imms, C.,
Reddihough, D., Cox, L., Carter, R.: Systematic review of the economic
impact of cerebral palsy. *Research in Developmental Disabilities*
80(June), 93–101 (2018). doi:10.1016/j.ridd.2018.06.012
6. Bayón, C., Raya, R., Lara, S.L., Ramírez, Ó., Serrano, J., Rocon, E.:
Robotic Therapies for Children with Cerebral Palsy: A Systematic
Review. *Translational Biomedicine* **7**(1), 1–10 (2016).
doi:10.21767/2172-0479.100044
7. Conner, B.C., Remec, N.M., Michaels, C.M., Wallace, C.W., Andrisevic,
E., Lerner, Z.F.: Relationship between ankle function and walking ability
for children and young adults with cerebral palsy: A systematic review
of deficits and targeted interventions. *Gait & Posture* **91**(October 2021),
165–178 (2022). doi:10.1016/j.gaitpost.2021.10.024
8. Rodda, J., Graham, H.K.: Classification of gait patterns in spastic
hemiplegia and spastic diplegia: A basis for a management algorithm.

- 1 European Journal of Neurology **8**, 98–108 (2001).
2 doi:10.1046/j.1468-1331.2001.00042.x
- 3 9. Morris, C., Bowers, R., Ross, K., Stevens, P., Phillips, D.: Orthotic
4 management of cerebral palsy: Recommendations from a consensus
5 conference. *NeuroRehabilitation* **28**(1), 37–46 (2011).
6 doi:10.3233/NRE-2011-0630
- 7 10. Wakeling, J., Delaney, R., Dudkiewicz, I.: A method for quantifying
8 dynamic muscle dysfunction in children and young adults with cerebral
9 palsy. *Gait & posture* **25**(4), 580–589 (2007).
10 doi:10.1016/J.GAITPOST.2006.06.009
- 11 11. Fowler, E.G., Staudt, L.A., Greenberg, M.B.: Lower-extremity selective
12 voluntary motor control in patients with spastic cerebral palsy :
13 increased distal motor impairment. *Developmental Medicine & Child
14 Neurology* **52**, 264–269 (2010). doi:10.1111/j.1469-8749.2009.03586.x
- 15 12. Kerkum, Y.L., Buizer, A.I., Noort, J.C.V.D., Becher, J.G.: The Effects of
16 Varying Ankle Foot Orthosis Stiffness on Gait in Children with Spastic
17 Cerebral Palsy Who Walk with Excessive Knee Flexion. *PLoS ONE*
18 (2015). doi:10.1371/journal.pone.0142878
- 19 13. Firouzeh, P., Sonnenberg, L.K., Morris, C., Pritchard-Wiart, L.: Ankle
20 foot orthoses for young children with cerebral palsy: a scoping review.
21 *Disability and Rehabilitation* **43**(5), 726–738 (2019).
22 doi:10.1080/09638288.2019.1631394
- 23 14. Meyns, P., Kerkum, Y.L., Brehm, M.A., Becher, J.G., Buizer, A.I.,
24 Harlaar, J.: Ankle foot orthoses in cerebral palsy: Effects of ankle
25 stiffness on trunk kinematics, gait stability and energy cost of walking.
26 *European Journal of Paediatric Neurology* **26**, 68–74 (2020).
27 doi:10.1016/j.ejpn.2020.02.009
- 28 15. Wright, E., DiBello, S.A.: Principles of Ankle-Foot Orthosis Prescription
29 in Ambulatory Bilateral Cerebral Palsy. *Physical Medicine and
30 Rehabilitation Clinics of North America* **31**(1), 69–89 (2020).
31 doi:10.1016/j.pmr.2019.09.007
- 32 16. Rodda, J.M., Graham, H.K., Carson, L., Galea, M.P., Wolfe, R.: Sagittal
33 gait patterns in spastic diplegia. *Journal of Bone and Joint Surgery -
34 Series B* **86**(2), 251–258 (2004). doi:10.1302/0301-620X.86B2.13878
- 35 17. Dobson, F., Morris, M.E., Baker, R., Graham, H.K.: Gait classification in
36 children with cerebral palsy: A systematic review. *Gait and Posture*
37 **25**(1), 140–152 (2007). doi:10.1016/j.gaitpost.2006.01.003
- 38 18. Kane, K.J., Lanovaz, J.L., Musselman, K.E.: Physical Therapists' Use
39 of Evaluation Measures to Inform the Prescription of Ankle-Foot
Orthoses for Children with Cerebral Palsy. *Physical and Occupational
Therapy in Pediatrics* **39**(3), 237–253 (2019).
doi:10.1080/01942638.2018.1463586
19. Totah, D., Menon, M., Jones-Hershinow, C., Barton, K., Gates, D.H.:
The impact of ankle-foot orthosis stiffness on gait: A systematic
literature review. *Gait and Posture* **69**(October 2018), 101–111 (2019).
doi:10.1016/j.gaitpost.2019.01.020
20. Carcreff, L., Gerber, C.N., Paraschiv-Ionescu, A., De Coulon, G.,
Newman, C.J., Aminian, K., Armand, S.: Comparison of gait
characteristics between clinical and daily life settings in children with
cerebral palsy. *Scientific Reports* **10**(1), 1–11 (2020).
doi:10.1038/s41598-020-59002-6
21. Carcreff, L., Gerber, C.N., Paraschiv-Ionescu, A., De Coulon, G.,
Kamiar, A., Newman, C.J., Armand, S.: Walking Speed of Children and
Adolescents With Cerebral Palsy: Laboratory Versus Daily Life.
Frontiers in Bioengineering and Biotechnology **8**(812) (2020)
22. Wren, T.A.L., Dryden, J.W., Mueske, N.M., Dennis, S.W., Healy, B.S.,
Rethlefsen, S.A.: Comparison of 2 Orthotic Approaches in Children
with Cerebral Palsy. *Pediatric Physical Therapy* **27**(3), 218–226 (2015).
doi:10.1097/PEP.000000000000153
23. Wang, X., Guo, S., Qu, B., Song, M., Qu, H.: Design of a Passive
Gait-based Ankle-foot Exoskeleton with Self-adaptive Capability.
Chinese Journal of Mechanical Engineering (English Edition) **33**(1)
(2020). doi:10.1186/s10033-020-00465-z
24. Alam, M., Choudhury, I.A., Mamat, A.B.: Mechanism and design
analysis of articulated ankle foot orthoses for drop-foot. *Scientific World
Journal* **14**(August) (2014). doi:10.1155/2014/867869
25. Svensson, W., Holmberg, U.: Ankle-foot-orthosis control in inclinations
and stairs. 2008 IEEE International Conference on Robotics,
Automation and Mechatronics, RAM 2008 (July), 301–306 (2008).
doi:10.1109/RAMECH.2008.4681479
26. Yeung, L.F., Ockenfeld, C., Pang, M.K., Wai, H.W., Soo, O.Y., Li, S.W.,
Tong, K.Y.: Randomized controlled trial of robot-assisted gait training
with dorsiflexion assistance on chronic stroke patients wearing
ankle-foot-orthosis. *Journal of NeuroEngineering and Rehabilitation*
15(1), 1–12 (2018). doi:10.1186/s12984-018-0394-7
27. Orekhov, G., Fang, Y., Cuddeback, C.F., Lerner, Z.F.: Usability and
performance validation of an ultra-lightweight and versatile untethered
robotic ankle exoskeleton. *Journal of NeuroEngineering and
Rehabilitation* **18**(1), 1–16 (2021). doi:10.1186/s12984-021-00954-9
28. Jackman, M., Sakzewski, L., Morgan, C., Boyd, R.N., Brennan, S.E.,
Langdon, K., Toovey, R.A.M., Greaves, S., Thorley, M., Novak, I.:
Interventions to improve physical function for children and young
people with cerebral palsy: international clinical practice guideline.
Developmental Medicine and Child Neurology, 1–14 (2021).
doi:10.1111/dmnc.15055
29. Hsieh, H.F., Shannon, S.E.: Three approaches to qualitative content
analysis. *Qualitative health research* **15**(9), 1277–1288 (2005).
doi:10.1177/1049732305276687
30. Venkatesh, V., Morris, M.G., Davis, G.B., Davis, F.D., Smith, R.H.,
Walton, S.M.: User Acceptance of Information Technology: Toward a
Unified View. *MIS Quarterly* **27**(3), 425–478 (2003)
31. Wolff, J., Parker, C., Borisoff, J., Mortenson, W.B., Mattie, J.: A survey
of stakeholder perspectives on exoskeleton technology. *Journal of
NeuroEngineering and Rehabilitation* **11**(1), 1–10 (2014).
doi:10.1186/1743-0003-11-169
32. Berthelot, J.M., Le Goff, B., Maugars, Y.: The Hawthorne effect:
Stronger than the placebo effect? *Joint Bone Spine* **78**(4), 335–336
(2011). doi:10.1016/J.JBSPIN.2011.06.001
33. Gonzalez, A., Garcia, L., Kilby, J., McNair, P.: Robotic devices for
paediatric rehabilitation: a review of design features. *BioMedical
Engineering Online* **20**(1) (2021). doi:10.1186/S12938-021-00920-5
34. Krumpal, I.: Determinants of social desirability bias in sensitive

1	surveys: a literature review. <i>Quality & Quantity</i> 2011 47:4 47 ,	1
2	2025–2047 (2011). doi:10.1007/S11135-011-9640-9	2
3	35. Sangeux, M., Rodda, J., Graham, H.K.: Sagittal gait patterns in	3
4	cerebral palsy: The plantarflexor–knee extension couple index. <i>Gait &</i>	4
5	<i>Posture</i> 41 (2), 586–591 (2015). doi:10.1016/j.gaitpost.2014.12.019	5
6	Additional/Supplementary files	6
7	Additional-File1.pdf	7
8	Final version of the English survey for Professionals stakeholder group (<i>G_P</i>).	8
9	Additional-File2.pdf	9
10	Final version of the English survey for end-users with CP and families (<i>G_U</i>).	10
11		11
12		12
13		13
14		14
15		15
16		16
17		17
18		18
19		19
20		20
21		21
22		22
23		23
24		24
25		25
26		26
27		27
28		28
29		29
30		30
31		31
32		32
33		33
34		34
35		35
36		36
37		37
38		38
39		39

Table 5 Qualitative themes from the content analysis. Frequency of mentioning for G_P , G_U and total normalized participation.

Theme	Associated categories	Percent		
		G_P	G_U	Total
OE1: Daily-life activities that would benefit from an improved gait performance				
<i>General mobility</i>	Walking, stairs, running, jumping	70.7%	62.1%	68.5%
<i>Leisure</i>	Play, sports	45.1%	24.1%	39.6%
<i>School</i>	Mobility at school	35.4%	20.7%	31.5%
<i>Equal social interaction</i>	Keep up with able bodied peers	25.6%	6.9%	20.7%
<i>Non-standard. terrains</i>	Parks, playgrounds, nature	19.5%	17.2%	18.9%
<i>Home</i>	Mobility between and inside home rooms	18.3%	10.3%	16.2%
<i>Other</i>	-	2.4%	0.0%	1.8%
OE2: Limitations of powered exoskeletons for daily-life use				
<i>Bulkiness</i>	Weight, volume	45.0%	47.1%	45.5%
<i>User friendliness</i>	Ease of use	41.7%	29.4%	39.0%
<i>Cost</i>	Purchase and reparation costs	33.3%	17.6%	29.9%
<i>Control</i>	Control requirements and manipulation	31.7%	17.6%	28.6%
<i>Adaptability</i>	Patient's needs, environment	23.3%	11.8%	20.8%
<i>Availability</i>	Getting access to its use	11.7%	11.8%	11.7%
<i>Flexibility and ROM</i>	Possibility of movements, compliance	6.7%	11.8%	7.8%
<i>Acceptance</i>	Approval by end-user	8.3%	0.0%	6.5%
<i>Durability</i>	Lifetime	6.7%	0.0%	5.2%
<i>Other</i>	-	8.3%	11.8%	9.1%
OE3: Limitations of passive AFOs for daily-life use				
<i>Adaptability</i>	Patient's needs, Environment	55.7%	36.4%	51.1%
<i>Flexibility and ROM</i>	Possibility of movements, compliance	31.4%	22.7%	29.3%
<i>Comfort</i>	Avoid pressure, friction, abrasions	21.4%	50.0%	28.3%
<i>Bulkiness</i>	Wearability, weight, volume	12.9%	31.8%	17.4%
<i>Energy cost</i>	-	20.0%	0.0%	15.2%
<i>Metrics</i>	Possibility of assessment while wearing	11.4%	4.5%	9.8%
<i>User friendliness</i>	Ease of use	10.0%	9.1%	9.8%
<i>Cost</i>	Purchase and reparation costs	7.1%	13.6%	8.7%
<i>Durability</i>	Lifetime	7.1%	4.5%	6.5%
<i>Walking</i>	Walking normal, functional	4.3%	9.1%	5.4%
<i>Other</i>	-	10.0%	13.6%	10.9%

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [AdditionalFile1.pdf](#)
- [AdditionalFile2.pdf](#)